MedTrace Logo

Fructose in Exercising Individuals With Type 1 Diabetes Using Insulin Degludec

NCT03497260 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-09-20

No results posted yet for this study

Summary

To determine and compare the time-to-hypoglycaemia (defined as plasma glucose \<3.9mmol/L) in individuals with type 1 diabetes treated with ultra-Long acting insulin degludec during aerobic exercise with or without prior ingestion of a single oral fructose load.

Conditions

  • Type 1 Diabetes Mellitus
  • Diabetes Complications

Interventions

DIETARY_SUPPLEMENT

Fructose

Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.

OTHER

Plain water

Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Christoph Stettler, MD · Inselspital, Bern University Hospital, University of Bern

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-04
Primary Completion
2019-09-06
Completion
2019-09-08

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03497260 on ClinicalTrials.gov